Drug Update · Oncology

FDA Approves Datopotamab Deruxtecan for Unresectable TNBC: 36% ORR

September 02, 2026

Approval date (most recent supplement)

2026-05-22

Trial

TROPION-Breast02

Objective response rate

36% vs 23% (investigator's choice chemotherapy)

Recommended dose

6 mg/kg IV every 3 weeks (max 540 mg)

Median duration of response

6.7 months vs 5.7 months

Clinical Perspective

This update affects oncology clinicians and breast cancer specialists treating adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy, as the label now includes this indication ^[2]^[4]. The source-confirmed data support that datopotamab deruxtecan produced a 36% objective response rate versus 23% with investigator’s choice chemotherapy and had a median duration of response of 6.7 months in the reported randomized trial ^[3]^[4]. What remains to be defined is how datopotamab deruxtecan should be sequenced relative to other systemic options and which patient subgroups derive the greatest benefit?

Dr. Meera Pillai, MBBS, MD (General Medicine), DM (Medical Oncology) · Oncology

The FDA approved datopotamab deruxtecan (Datroway) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy, with the most recent supplemental approval dated 2026-05-22 ^[2]^[4]. The approval references randomized trial evidence including an objective response rate of 36% with datopotamab deruxtecan versus 23% with investigator’s choice chemotherapy ^[3]^[4].

Clinical Context

Datopotamab deruxtecan (Datroway) is a Trop-2-directed antibody and topoisomerase I inhibitor conjugate (antibody-drug conjugate) developed by Daiichi Sankyo and marketed in collaboration with AstraZeneca ^[2]^[1]. The product is supplied as a 100 mg lyophilized vial and is administered intravenously; the approved dosage is 6 mg/kg (up to a maximum of 540 mg for patients ≥90 kg) every 3 weeks ^[2]^[4]. Clinicians should consult current prescribing information for full dosing guidance. The regulatory action in May 2026 updated the label to include unresectable or metastatic TNBC for patients who are not candidates for PD-1/PD-L1 inhibitor therapy; clinical evidence supporting activity includes randomized trial data with objective response rate and duration of response endpoints reported by the sponsor and FDA ^[2]^[3]^[4].

Key Findings

The TROPION-Breast02 trial showed datopotamab deruxtecan achieved a 36% objective response rate versus 23% with investigator’s choice chemotherapy in patients with unresectable or metastatic TNBC ^[3]^[4].
Median duration of response was 6.7 months with datopotamab deruxtecan and 5.7 months with chemotherapy as reported by the FDA summary ^[3].
The randomized TROPION-Breast02 trial enrolled 644 patients randomized 1:1 to DATROWAY 6 mg/kg (N=323) or investigator’s choice single-agent chemotherapy (N=321) including paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin; the major efficacy outcomes were progression-free survival and overall survival with additional outcomes including objective response rate ^[4].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

The most common adverse reactions (≥20%), including laboratory abnormalities, reported in patients with TNBC were stomatitis, increased amylase, nausea, alopecia, decreased hemoglobin, decreased white blood cells, constipation, decreased calcium, decreased lymphocytes, fatigue, decreased neutrophils, increased ALT, increased AST, dry eye, keratitis, decreased albumin, vomiting, musculoskeletal pain, decreased sodium, and increased blood alkaline phosphatase ^[2]^[3].
DATROWAY can cause interstitial lung disease (ILD)/pneumonitis; monitor for new or worsening respiratory symptoms and initiate corticosteroids if ILD/pneumonitis is suspected; permanently discontinue for confirmed Grade 2 or higher ILD/pneumonitis ^[2].
Ocular adverse reactions reported include dry eye, keratitis, blepharitis, meibomian gland dysfunction, increased lacrimation, conjunctivitis, and blurred vision; patients should use preservative-free lubricating eye drops and avoid contact lenses during treatment unless advised by an eye specialist ^[2]^[1].
Stomatitis and mouth ulcers are common; patients are advised to use a steroid-containing mouthwash and to hold ice chips/ice water in the mouth during infusion ^[1]^[2].

Study Design

TROPION-Breast02 was a multicenter, open-label, randomized trial that enrolled 644 patients with unresectable or metastatic TNBC who had not received prior systemic therapy for unresectable or metastatic disease; patients were randomized 1:1 to receive DATROWAY 6 mg/kg (N=323) or investigator’s choice single-agent chemotherapy (N=321) ^[4]. Clinicians should consult current prescribing information for full dosing guidance. Randomization was stratified by geographical region, PD-L1 status, and disease-free interval history; the major efficacy outcomes were progression-free survival and overall survival with additional outcomes including objective response rate as assessed by blinded independent central review ^[4]. The approved dose in the label is 6 mg/kg administered intravenously every 3 weeks ^[2]^[4].

FAQ

Q1 What is datopotamab deruxtecan (Datroway) approved for?

Datopotamab deruxtecan (Datroway) is approved for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The label also includes indications for locally advanced or metastatic EGFR-mutated NSCLC and unresectable or metastatic HR-positive, HER2-negative breast cancer. The most recent supplemental approval date in the label metadata is 2026-05-22.

Q2 How does datopotamab deruxtecan work?

Datopotamab deruxtecan is a Trop-2-directed antibody-drug conjugate composed of a humanized anti-Trop-2 IgG1 antibody linked to a membrane-permeable topoisomerase I inhibitor (DXd) via a cleavable linker. After binding Trop-2 on tumor cells, the ADC is internalized and the linker is cleaved intracellularly, releasing DXd to cause DNA damage and apoptotic cell death.

Q3 What is the recommended dose of datopotamab deruxtecan?

The recommended dosage of datopotamab deruxtecan (DATROWAY) is 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle), with a maximum of 540 mg for patients weighing ≥90 kg. Dosing modifications for adverse reactions and administration details are provided in the prescribing information. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the side effects of datopotamab deruxtecan?

The most common adverse reactions reported in patients with TNBC included stomatitis, increased amylase, nausea, alopecia, decreased hemoglobin, decreased white blood cells, constipation, decreased calcium, decreased lymphocytes, fatigue, decreased neutrophils, increased ALT, increased AST, dry eye, keratitis, decreased albumin, vomiting, musculoskeletal pain, decreased sodium, and increased alkaline phosphatase. Serious risks include interstitial lung disease/pneumonitis and ocular adverse reactions including keratitis; monitoring and dose modifications are described in the label.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves Datopotamab Deruxtecan for Unresectable TNBC: 36% ORR

Direct Clinical Takeaway & Evidence Summary

FDA Approves Datopotamab Deruxtecan for Unresectable TNBC: 36% ORR

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Oncology in your inbox.

Related Clinical Updates

FDA Approves vepdegestrant for ESR1‑mutant ER+ Breast Cancer: PFS HR 0.57

MARIPOSA: Lazertinib + Amivantamab Reduced Progression Risk HR 0.70 vs Osimertinib in EGFR‑mutant NSCLC

FDA Approves vepdegestrant for ER‑positive, HER2‑negative, ESR1‑mutated Metastatic Breast Cancer: PFS HR 0.57 in VERITAC-2

Verified HCP Portal